Additionally, trials using vitexin as a pre-treatment showed a reduction in fibrosis (collagen type I Col I, TGF-β1), as well as a decrease in ferroptosis, ROS, Fe2+, and MDA levels, with an increase in GSH levels in rats with diabetic nephropathy [89]. Here, TGFB1 is linked to diabetic kidney disease.